

PHARMACEUTICAL GLASS

SCHOTT drives further growth with advanced pharma solutions

International technology group SCHOTT continues to make waves throughout the pharma industry as a globally-favoured partner for advanced drug containment solutions and drug delivery systems.





Throughout 2021 the company played a key role in fighting the pandemic by delivering glass vials for over 5 billion COVID-19 vaccine doses. It also paved the way for advanced packaging solutions, thus enabling the next generation of drugs - and mRNA-based formulations besides. Now, following an increasing worldwide demand for high-quality pharma solutions, SCHOTT is announcing a further major investment, namely the company's China plans to triple production capacity for vials and ampoules. "We stay one step ahead by investing in our global production network and through our close collaborations with major drug makers and partners from the pharma industry," said Andreas Reisse, Executive Vice President of SCHOTT's Pharma business unit. "Together, we strive to improve global health for everyone."

Here both packaging and delivery solutions are integral to every drug, given that they go through the regulatory approval process together. Also, in order to prolong drug lifecycle, many pharma companies rely upon different containment solutions. For example, a drug may enter the market within a vial only to be then stored in prefillable syringes that will render its administration easier. Here questions of the right packaging material, glass or polymer all remain vital. "With new drug categories like mRNA-based formulations entering the market," adds Reisse "our holistic approach with a broad range of packaging systems -including both glass and polymer options- allows us to find a tailored solution for individual needs."

THINKING AHEAD

SCHOTT supports pharma manufacturers in making the best possible decision going for-

ward by compiling comprehensive analytics while constantly innovating with new packaging solutions. For instance, the company's latest addition, EVERIC® care vials, features a hydrophobic coating on the inside of the vial that protects highly-sensitive drugs - like biologics.

MAJOR EXPANSIONS PLANNED TO INCREASE STERILE SOLUTIONS CAPACITY

In 2021, SCHOTT tripled its capacity for pre-sterilized, ready-to-use glass vials in the USA – all to meet a steady growth in market demand for such high-value solutions. The company enhanced its portfolio still further, expanding the capacity of prefillable glass syringes by 50 percent in Switzerland in order to strengthen the supply of much sought-after drug delivery systems. Not only. Spring 2022 is set to see a state-of-the-art pro-

PHARMACEUTICAL GLASS



duction site for prefillable high quality polymer syringes inaugurated in Germany. SCHOTT will also be adding new modules to its production network of 16 global plants. Here the company has recently broken ground for a new module in China, which is designed to triple the production capacity. This double-digit, million Euro project is scheduled to be completed by the end of 2022.

ACCELERATING INDUSTRY GROWTH

SCHOTT's close, long-standing relationships with key drug makers continue to establish new partnerships - much like the company's joint venture with Serum Institute, India, the world's largest vaccines producer. "Sensing the pulse of the industry, we encourage opportunities that can secure the supply of containment and drug delivery solutions while setting new standards in the industry

thanks to our collaborations," explains Reisse.

PIONEERING. RESPONSIBLY. TOGETHER

All these attributes characterize SCHOTT as a high-tech materials manufacturer based upon specialty glass. Having become the pioneer of an entire industry, the company's founder, Otto Schott, is considered its inventor. Today, opening new markets and applications with the same pioneering spirit and passion continues to drive SCHOTT's glasslovers - just as it's consistently done for over 130 years. Currently represented in 34 countries, the company is a much-skilled partner of such high-tech industries as Healthcare, Home Appliances & Living, Consumer Electronics, Semiconductors & Datacom, Optics, Industry & Energy, Automotive, Astronomy & Aerospace.

Over the fiscal year 2021, its 17.300 employees generated

sales amounting to EUR 2.5 billion. With the best teams, supported by the most advanced digital tools, the group intends to continue to grow. SCHOTT AG is owned by the Carl Zeiss Foundation, one of the oldest in Germany, which uses the Group's dividends to promote science. As a foundation company SCHOTT has an anchored responsibility, deep within its DNA, for employees, society and the environment. Its goal is to become a climate-neutral company by 2030. ■

SCHOTT
glass made of ideas

Schott AG

Hattenbergstrasse 10
55122 Mainz - Germany
Tel.: +49-6131-661589
Fax: +49-6131-662025
E-mail: info@schott.com

www.schott.com